Silo Pharma Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
SILO
- Investments
-
5
- Share Price
-
$1.74
- (As of Friday Closing)
Silo Pharma General Information
Description
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Contact Information
Website
www.silopharma.comCorporate Office
- 677 North Washington Boulevard
- Sarasota, FL 34236
- United States
Corporate Office
- 677 North Washington Boulevard
- Sarasota, FL 34236
- United States
Silo Pharma Timeline
Silo Pharma Stock Performance
As of 20-Nov-2026, Silo Pharma’s stock price is $1.74. Its current market cap is $3.69M with 2.16M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.74 | $1.88 | $1.10 - $10.42 | $3.69M | 2.16M | 65.8K | -$2.29 |
Silo Pharma Financials Summary
As of 30-Sep-2026, Silo Pharma has a trailing 12-month revenue of $36.1K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,785) | (1,410) | (4,024) | (4,294) |
| Revenue | 36 | 72 | 72 | 72 |
| EBITDA | (3,836) | (4,373) | (4,715) | (4,025) |
| Net Income | (3,720) | (4,228) | (4,393) | (3,701) |
| Total Assets | 8,796 | 7,605 | 7,412 | 7,746 |
| Total Debt | 0 | 0 | 0 | 0 |
Silo Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Silo Pharma Comparisons
Industry
Financing
Details
Silo Pharma Competitors (3)
One of Silo Pharma’s 3 competitors is Marinus Pharmaceuticals, a Private Equity-Backed company based in Radnor, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Ovid Therapeutics | Formerly VC-backed | New York, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA |
Silo Pharma Patents
Silo Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026152055-A1 | Combination therapy against stress-induced pathophysiology | Pending | 13-Jan-2025 | ||
| US-20250288540-A1 | Methods and compositions for pain management | Pending | 13-Mar-2024 | ||
| US-20240252579-A1 | Use of cns-homing targeting peptides for treating neurological disorders | Pending | 30-Jan-2023 | ||
| US-20240058469-A1 | Use of psilocybin in cancer treatment | Pending | 13-Dec-2020 | ||
| WO-2022125949-A1 | Use of psilocybin in cancer treatment | Inactive | 13-Dec-2020 | A61P35/00 |
Silo Pharma Signals
Silo Pharma Investments & Acquisitions (5)
Silo Pharma’s most recent deal was a Merger/Acquisition with Qwikagents for . The deal was made on 15-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Qwikagents | 15-Apr-2026 | Merger/Acquisition | Application Software | ||
| Obesity Treatment Development (Hoth Therapeutics / Silo Pharma) | 25-Jun-2025 | Joint Venture | Drug Discovery | ||
| Joint Venture (Silo Pharma / Zylo Therapeutics) | 11-Aug-2021 | Joint Venture | Drug Discovery | ||
| Blind Faith Concepts | 20-Dec-2018 | Merger/Acquisition | Footwear | ||
| NFID Brands | 29-Sep-2018 | Merger/Acquisition | Clothing |
Silo Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
44.17 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Silo Pharma Exits (2)
Silo Pharma’s most recent exit was on 20-Dec-2018 from Blind Faith Concepts. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Blind Faith Concepts | 20-Dec-2018 | Completed |
|
||
| NFID Brands | 29-Sep-2018 | Merger/Acquisition | Completed |
Silo Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Qwikagents |
Silo Pharma FAQs
-
When was Silo Pharma founded?
Silo Pharma was founded in 2010.
-
Where is Silo Pharma headquartered?
Silo Pharma is headquartered in Sarasota, FL.
-
What is the size of Silo Pharma?
Silo Pharma has 3 total employees.
-
What industry is Silo Pharma in?
Silo Pharma’s primary industry is Drug Discovery.
-
Is Silo Pharma a private or public company?
Silo Pharma is a Public company.
-
What is Silo Pharma’s stock symbol?
The ticker symbol for Silo Pharma is SILO.
-
What is the current stock price of Silo Pharma?
As of 20-Nov-2026 the stock price of Silo Pharma is $1.74.
-
What is the current market cap of Silo Pharma?
The current market capitalization of Silo Pharma is $3.69M.
-
What is Silo Pharma’s current revenue?
The trailing twelve month revenue for Silo Pharma is $36.1K.
-
Who are Silo Pharma’s competitors?
Marinus Pharmaceuticals, Ovid Therapeutics, and Neurona Therapeutics are competitors of Silo Pharma.
-
What is Silo Pharma’s annual earnings per share (EPS)?
Silo Pharma’s EPS for 12 months was -$2.29.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process